PubMed Health⌕ Search

Biomedical subjects

K Rothman

Publications and source records attributed to K Rothman.

9 recordsLinked to original sources
PubMed1995

Massive papillary dermal fatty infiltration in a patient with psoriasis.

A 36-year-old Caucasian man presented with chronic, slightly erythematous, scaly plaques of 6 years duration. Some improvement was noticed after treatment with topical steroids. Differential clinical diagnoses included psoriasis and eczema. A biopsy revealed psoriasiform changes with "fatty vacuoles" replacing the papillary dermis. The histogenesis of these findings is unknown. Even though small foci of fatty vacuolization have been observed in association with heavy inflammatory infiltrates in skin, this is the first reported case of massive fatty infiltrates in a non-neoplastic disorder of the skin associated with only sparse inflammatory infiltrate.

Adipocytes↗
PubMed1986

The diagnosis and treatment of chancroid.

Chancroid, a disappearing disease in the United States, was reintroduced into the country in 1980 by immigrants from the Caribbean, Mexico, and Southeast Asia. Point epidemics resulted, each of them associated with prostitution. During the 4-month period between March 1 to June 30, 1985, forty-five patients were diagnosed and treated in Massachusetts, thirty-seven from Boston alone. By means of these case records, the morphologic characteristics, laboratory diagnosis, and treatment regimens are described.

Adult↗
PubMed1982

Clinical trial of Corynebacterium parvum (intra-lymph-node and intravenous) and radiation therapy in the treatment of head and neck carcinoma.

Fifty-seven patients with previously untreated squamous cell carcinoma of the head and neck region of all clinical stages were entered a trial to evaluate the effectiveness of Corynebacterium parvum combined with radiation therapy in improving local and survival results. Twenty-nine patients were randomized to receive radiation therapy alone, and 28 patients were randomized to receive radiation therapy combined with C. parvum. The C. parvum was administered into the tumor-bearing lymph nodes of the neck or into the cervical node region in non-node-positive patients (4 mg/m2) and by intravenous routes (at 2, 2, 4, 4 and 4 mg/M2) at days -10, -7, and -3 before, and at +7 and +14 days after the start of radiation therapy. The study began in July 1975 and was terminated after 2 1/2 years of patient accession. The statistical analysis showed that those receiving C. parvum were not doing better than controls and, in fact, in some subgroups there was concern that they might be doing less well. Pertinently, analysis showed that those receiving C. parvum would not experience the 25% point improvement in disease-free survival frequency which had been stipulated in the design of the protocol.

Aged↗
PubMedDate not supplied

Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53.

Cancer cells containing mutated p53 are sensitive to the re-introduction of the wild-type (wt) p53. We sought to determine whether ovarian cancer cells that retain wt p53 are sensitive to the re-introduction of wt p53. Our results demonstrated that A2780 and PA-1 cells, which retain wt p53, are more resistant to apoptosis and growth suppression induced by exogenous expression of wt p53 than SKOV-3 and Caov-3 cells that contain mutated p53. All cell lines, except PA-1, showed induction of the p53-targeted genes. Further, inhibitors of p53-dependent apoptosis, mdm2 and Bcl-xL were not overexpressed in A2780 and PA-1 cells. These results suggest that one major defect in PA-1 cells is due to abrogation of induction of the p53-targets which is independent of mdm2 and Bcl-xL. Although A2780 cells showed induction of the p53-targeted genes, the cleavage of caspase-9 was undetectable. Therefore, p53-dependent apoptosis may be blocked upstream or at the caspase-9 level in A2780 cells.

Adenoviridae↗